Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Nasdaq: AGIO
Analyst Coverage
Canaccord GenuityJohn Newman, Ph.D.
CowenEric Schmidt, Ph.D.
Credit SuisseAlethia Young
Goldman SachsTerence Flynn, Ph.D.
Janney Montgomery Scott Debjit Chattopadhyay
JP MorganAnupam Rama
Leerink Swann & CompanyMichael Schmidt, Ph.D.
Needham & CompanyChad Messer, Ph.D.
Oppenheimer & Co.Leah Rush Cann
SunTrust Robinson HumphreyYatin Suneja
Stock Information
Change: - 1.89 (3.25%)
NASDAQ: AGIO (Common Stock)
Data as of07/27/174:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.